Uptake Medical is a medical device company focused on enhancing the quality of life for patients with pulmonary diseases through innovative therapies. Their primary technology, Bronchoscopic Thermal Vapor Ablation® (InterVapor® or BTVA®), is a non-surgical and non-implant procedure designed to treat conditions such as emphysema and lung cancer. This technique involves the application of heated pure water vapor to targeted lung tissue, which effectively ablates diseased areas. The procedure is minimally invasive, typically lasting less than 15 minutes and can be performed under light sedation, making it accessible for patients who may not be candidates for more invasive surgical options.

The vapor ablation process works by delivering steam through a bronchoscope to the affected regions of the lung, leading to the removal of damaged tissue through the body’s natural healing mechanisms. For patients suffering from severe emphysema, this treatment can result in significant improvements in pulmonary function and overall breathing, thereby enhancing their quality of life. While the InterVapor technology shows promise in clinical settings, it is important to note that it is not currently approved for use in the United States.

United States

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. 

Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

Uptake Medical

Company Details